Search Results
Your search for ,WHo matches 20676 pages
Showing 8051 - 8100Pemigatinib for Previously Treated Cholangiocarcinoma With FGFR2 Rearrangement or Fusion
On April 17, 2020, pemigatinib was granted accelerated approval for the treatment of adults with previously treated unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by a U.S. Food and Drug...
AACR Virtual Annual Meeting I Draws Over 61,000 Registrants
The American Association for Cancer Research (AACR) announced that its first-ever Virtual Annual Meeting attracted a vast worldwide audience, with more than 61,000 registrants from 140 countries. Held April 27 and 28, the 2-day meeting featured practice-changing clinical trials, innovative basic...
Evolving Insights Into COVID-19 and Cancer Care
Pulling together the 2020 American Association of Cancer Research (AACR) Virtual Annual Meeting in less than 1 month was a Herculean task, and an important component was producing a session on COVID-19 and cancer care. This special session involved researchers from the front lines of the pandemic...
Expert Point of View: Thomas J. Herzog, MD
Thomas J. Herzog, MD, Deputy Director, University of Cincinnati Cancer Center, who presented a distillation of the PRIMA trial data along with updated results of the phase III PAOLA-1 trial of olaparib plus bevacizumab maintenance, called the data “practice-changing.” “We’ve suspected for a while...
Niraparib as First-Line Maintenance Therapy for Advanced Ovarian Cancers
Making sense of maintenance therapy in advanced ovarian cancer has been a tall order since the publication of impressive data for not one but three PARP inhibitors at the European Society for Medical Oncology (ESMO) 2019 Congress.1 The picture became a little clearer on April 29, 2020, however,...
Expert Point of View: Pamela N. Munster, MD
Formal I-SPY 2 trial discussant, Pamela N. Munster, MD, Professor in the Department of Medicine, University of California, San Francisco, found the study promising but said confirmatory trials are needed. “What we know so far in preoperative therapy for breast cancer is that pathologic complete...
WEE1 Inhibitor Shows Activity in Recurrent Uterine Serous Carcinoma
Monotherapy with the experimental WEE1 inhibitor adavosertib has shown activity in patients with advanced recurrent or metastatic uterine serous carcinoma,1 according to data presented during the 2020 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer Webinar Series. The initial ...
Overcoming the Challenges of Presenting the ASCO Annual Meeting During the COVID-19 Pandemic
As the worldwide cases of the coronavirus started to mount in February and March, medical societies and organizations monitoring the escalating COVID-19 pandemic and its impact on international and domestic travel made the difficult decision to postpone or cancel their scientific conferences. On...
United Against Cancer to Accelerate Progress for Patients
When I chose my Presidential theme for the 2020 ASCO Annual Meeting, “Unite and Conquer: Accelerating Progress Together,” in early 2019, I never imagined it would take on a new meaning 12 months later. The world is grappling with the COVID-19 pandemic, and, even as we practice social distancing, I...
Prevalence of Endosalpingiosis and Association With Ovarian Cancer
Over the last decade, researchers have become concerned about a possible link between a benign gynecologic lesion called endosalpingiosis and ovarian cancer. However, using a diagnostic method typically reserved for specimens suspected of being cancerous, a team has found the prevalence of...
Neoadjuvant Atezolizumab Plus Chemotherapy for Resectable NSCLC
In a phase II study reported in The Lancet Oncology, Shu et al found that neoadjuvant treatment with atezolizumab plus nab-paclitaxel/carboplatin produced a major pathologic response in 57% of patients and a complete pathologic response in 33% of patients with resectable, predominantly stage IIIA...
Lessons Learned on Rotation at COVID-19 Inpatient Service at New York City Hospital
AS I WRITE TO YOU, I am happy to report I have just completed a 7-day rotation at the COVID-19 inpatient service at my hospital in New York City! Overall, it was a positive experience, despite the occasional sad and scary moments. I left the service feeling uplifted and fulfilled. I am glad to have ...
Antihistamines May Improve Survival Among Patients With Malignant Melanoma
In a research letter published by Fritz et al in the journal Allergy, researchers reported that the common allergy medications desloratadine and loratadine may be associated with improved survival in patients with malignant melanoma. “Previous studies have shown that the same antihistamines have...
Do Marital Status and Race Affect the Treatment of Esophageal Cancer?
A study using data from the Michigan state cancer registry, reported in JCO Oncology Practice by Paniagua Cruz et al, found that a higher proportion of white vs black patients with esophageal cancer were married; that single patients were less likely to receive esophagectomy and chemotherapy; and...
COVID-19 Infection in Pediatric Patients With Cancer
In a study reported in a research letter in JAMA Oncology, Boulad et al found a low rate of COVID-19 morbidity among infected pediatric patients with cancer seen in the Memorial Sloan Kettering Cancer Center pediatric program, as well as a low rate of infection in patients without COVID-19...
Online Guide Offers Tips for Communicating With Patients During the COVID-19 Pandemic
A NEW ONLINE GUIDE provides tips to help oncology and other clinicians navigate the difficult and distressing communications with patients that have arisen during the COVID-19 pandemic. Anthony Back, MD, a medical oncologist and palliative medicine specialist at the University of Washington and...
New ASCO Guideline Addresses Head/Neck Squamous Cell Carcinoma of Unknown Primary
ASCO has released a new clinical guideline titled, “Diagnosis and Management of Squamous Cell Carcinoma of Unknown Primary in the Head and Neck: ASCO Guideline.”1 The guideline, promulgated by an international expert panel, is intended to “provide evidence-based recommendations to practicing...
Atezolizumab Plus Bevacizumab vs Sorafenib in Treatment-Naive Patients With Unresectable Hepatocellular Carcinoma
As reported in The New England Journal of Medicine by Richard S. Finn, MD, and colleagues, the phase III IMbrave150 trial has shown that anti–programmed cell death ligand 1 (PD-L1) plus anti-VEGF therapy with atezolizumab plus bevacizumab improved progression-free and overall survival vs sorafenib ...
ASCO Special Report Provides Guidance to Oncology Practices on Resuming Cancer Care During the COVID-19 Pandemic
ASCO has released the ASCO Special Report: A Guide to Cancer Care Delivery During the COVID-19 Pandemic, which provides detailed guidance to oncology practices on the immediate and short-term steps that could be taken to help protect the safety of patients and health-care staff before resuming more ...
Do Men Treated With ADT for Prostate Cancer Have a Lower Risk of Acquiring COVID-19?
A study of 4,532 men in the Veneto region of Italy has found that those who were being treated for prostate cancer with androgen-deprivation therapies (ADT) were less likely to develop COVID-19, and if they were infected, their disease tended to be less severe. This research was published by...
FDA Approves Olaparib for HRR Gene–Mutated Metastatic Castration-Resistant Prostate Cancer
On May 19, the U.S. Food and Drug Administration (FDA) approved olaparib (Lynparza) for adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene–mutated metastatic castration-resistant prostate cancer who have had disease progression...
Low-Intensity Surveillance as an Option for Some Patients With Non–Muscle Invasive Bladder Cancer
Low-intensity cystoscopic surveillance may be a viable option for patients with high-risk, non–muscle invasive bladder cancer, according to data from a paper presented to the media during a special session moderated by the American Urological Association (AUA) on May 15. The research was also...
Can Pain After Prostatectomy or Nephrectomy Be Managed Without Opioids?
The use of opioids continues to be major issue facing patients with cancer in the United States. Most patients undergoing prostate and kidney removal may be managed effectively without opioids during the postoperative period, according to new data from researchers in Pittsburgh highlighted during a ...
Detecting Relapse in Patients With Lymphoma in First Remission: Value of Surveillance Laboratory Testing
In a single-institution retrospective study reported in JCO Oncology Practice, Lynch et al found that routine laboratory surveillance testing had limited value in detecting relapse in patients with classical Hodgkin lymphoma in first remission. Study Details The study involved 235 patients at...
FDA Approves Atezolizumab for the First-Line Treatment of Patients With Metastatic NSCLC and High PD-L1 Expression
On May 18, the U.S. Food and Drug Administration (FDA) approved atezolizumab (Tecentriq) for the first-line treatment of adult patients with metastatic non–small cell lung cancer (NSCLC) whose tumors have high programmed cell death ligand 1 (PD-L1) expression (PD-L1 stained ≥ 50% of tumor cells or...
Qi Liu, PhD, on NSCLC: Pneumonitis, Immunotherapy, and Chemotherapy
Qi Liu, PhD, of the U.S. Food and Drug Administration, discusses data that suggest that patients with advanced non–small cell lung cancer who had a past medical history of pneumonitis were more likely to experience treatment-associated pneumonitis in response to immune checkpoint inhibitors or...
Physical Activity and Neurocognitive Function in Adult Survivors of Childhood Cancers
In a Childhood Cancer Survivor Study analysis reported in the Journal of Clinical Oncology, Barlow-Krelina et al found that consistent physical activity vs consistent inactivity was associated with reduced neurocognitive problems and greater improvement in neurocognitive domains during long-term...
FDA Pipeline: Two Breakthrough Therapy Designations for Fam-Trastuzumab Deruxtecan-nxki, and More
Over the past few weeks, the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designations for an antibody-drug conjugate in the treatment of gastric and lung cancers. The Agency has also issued Orphan Drug designations for agents being investigated in chronic myeloid...
Cancer Care at Tata Memorial Centre During the COVID-19 Pandemic
In correspondence published in The New England Journal of Medicine, two practitioners from Tata Memorial Centre, India’s largest cancer center, describe measures taken to continue providing cancer care during the COVID-19 pandemic in India. As related by the authors, scaling back of operations at...
FDA Approves Rucaparib in BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
On May 15, the U.S. Food and Drug Administration (FDA) granted accelerated approval to rucaparib (Rubraca) for patients with deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer who have been treated with androgen receptor–directed therapy...
FDA Approves Ripretinib for Previously Treated Patients With Advanced Gastrointestinal Stromal Tumor
On May 15, the U.S. Food and Drug Administration (FDA) approved ripretinib (Qinlock) for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib. INVICTUS Trial Efficacy was...
Selected Poster Presentations on Cancer Therapeutics and More
Although the live 2020 National Comprehensive Cancer Network (NCCN) Annual Conference was canceled, more than 100 posters scheduled for presentation are now available online, as part of the NCCN 2020 Virtual Annual Conference. The ASCO Post has summarized some of the clinical trial updates we found ...
10 Changes I Will Make in My Oncology Practice as a Result of COVID-19
As a result of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, or COVID-19) global pandemic, medicine—including oncology practice—will never be the same. We find ourselves in a time of emergency medicine for all specialties, technologic innovation (eg, more prevalent use of...
Study Finds a High Rate of Intra- and Postoperative Conversions to Total Thyroidectomy
The overall risk of needing a total thyroidectomy was found to be 19.4% for patients undergoing lobectomy for indeterminate and high-risk thyroid nodule, according to a report published by Moore et al in the World Journal of Surgery. The study also found that 21% and 26.5% of patients originally...
FDA Approves Pomalidomide for Kaposi Sarcoma
On May 14, 2020, the U.S. Food and Drug Administration (FDA) expanded the indication of pomalidomide (Pomalyst) to include treating adult patients with acquired immunodeficiency syndrome (AIDS)-related Kaposi sarcoma after failure of highly active antiretroviral therapy and those with Kaposi...
New Study Shows Patients With Cancer Had Lower Rates of Detected COVID-19 Antibodies vs Health-Care Workers
Results from an analysis involving both patients with cancer and health-care workers at Centre Léon Bérard in Lyon, France, showed that patients with cancer had a significantly lower detection rate of SARS-CoV-2 antibodies 15 days or more after COVID-19 symptoms and a positive reverse transcription ...
Combining Pembrolizumab With IL-12 Electroporation May Improve Clinical Response in Patients With Immunologically 'Cold' Melanoma
Patients with non–immune-infiltrated “cold” tumors have low frequencies of intratumoral tumor-reactive, checkpoint-positive cytotoxic lymphocytes, making them less responsive to checkpoint blockage than patients with immune-infiltrated “hot” tumors. A phase II study by Alain P. Algazi, MD, and...
Effectiveness of Different Severity Thresholds for Chemotherapy-Related Symptom Alerts
In a study reported in JCO Oncology Practice, Shi et al found that use of higher-than-currently-recommended severity thresholds for symptom alerts for patients receiving outpatient chemotherapy would result in failure to identify and treat many patients requiring clinical intervention for ...
Quitting Smoking at Any Point Improves Lung Cancer Survival, Study Finds
People who quit smoking at any time—even 2 years before a lung cancer diagnosis—improve their chances of survival after being diagnosed with the disease, according to the results of a large international study presented by Fares et al in a press briefing in advance of the ASCO20 Virtual Scientific...
Videoconference Intervention Can Reduce Levels of Anxiety and Distress Among Distance Caregivers
According to the National Alliance for Caregiving, the number of adult individuals in the United States providing care for patients with cancer ranges between 2.8 million and 6.1 million. Caregivers for patients with cancer who live more than 1 hour away report having higher levels of anxiety and...
Expert Point of View: William Dale, MD, PhD
"We have known for a long time, based on good evidence, that geriatric assessment is good at accurately identifying patients at high risk for chemotherapy-induced toxicity, surgical complications, and increased hospitalizations. This study adds an intervention component based on the geriatric...
Geriatrician Assessment and Integrated Care May Help Older Patients as Well as the Health-Care System
A full geriatric assessment and geriatrician-led multidisciplinary care improved the quality of life of patients aged 70 and older undergoing chemotherapy, targeted therapy, or immunotherapy, according to results of a prospective, randomized, controlled, open-label trial, reported in a press...
Expert Point of View: Don S. Dizon, MD, FACP, FASCO
Commenting on the SOLO2 trial for The ASCO Post was Don S. Dizon, MD, FACP, FASCO, Director of Women’s Cancers at Lifespan Cancer Institute and Professor of Medicine at Brown University, Providence, Rhode Island. “It’s great to get an overall survival advantage from a PARP inhibitor study. Coming...
Overall Survival Benefit Shown for Maintenance Olaparib in Ovarian Cancer
For the first time, overall survival has been improved with maintenance therapy involving a poly (ADP-ribose) polymerase (PARP) inhibitor in patients with platinum-sensitive recurrent ovarian cancer associated with BRCA1/2 mutations. In the final, preplanned, overall survival analysis in the...
Cancer vs COVID-19: Clinical Trial Research During the Pandemic
The COVID-19 pandemic transformed cancer care, seemingly overnight, as practices scrambled to ensure a safe environment for caregivers and patients. Although regulatory burdens have been relaxed to allow patients to continue on trial treatment and telemedicine has expanded its competency and reach, ...
AACR 2020: Continuous Dosing of Dabrafenib Plus Trametinib Improves Progression-Free Survival vs Intermittent Dosing in Advanced Melanoma
Continuous dosing with dabrafenib and trametinib improved progression-free survival in patients with BRAF-mutated advanced melanoma compared with an intermittent-dosing strategy, according to results of the phase II SWOG S1320 randomized trial reported at the opening Plenary Session of the 2020...
Don’t Touch Me With a 6-Foot Pole
The universe has an intriguing way of registering our wishes and delivering them in convoluted, mutated forms. Last winter, I recall coming home after a long day at the hospital and being ambushed by my 3-year-old daughter and preteen son. She wanted to play, he needed help with homework, and they ...
Can Communication Skills Training for Oncologists Improve Discussion of Goals of Care for Patients With Advanced Cancer?
In a study reported in JCO Oncology Practice, Bickell et al found that providing oncologists with communication skills training did not improve the frequency or quality of goals-of-care discussions for patients with advanced cancer. Study Details In the study, 22 oncologists were randomly assigned...
Can a Culturally Tailored Education Program Improve Colorectal Cancer Awareness and Screening?
People who received information from the Screen to Save program, a culturally tailored initiative from the National Cancer Institute (NCI) Center to Reduce Cancer Health Disparities (CRCHD), increased their knowledge of colorectal cancer and indicated willingness to adopt potentially preventive...
FDA Approves Selpercatinib for Lung and Thyroid Cancers With RET Mutations or Fusions
On May 8, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to selpercatinib (Retevmo) for the following indications: Adult patients with metastatic RET fusion–positive non–small cell lung cancer (NSCLC) Adult and pediatric patients ≥ 12 years of age with advanced or...
